Cargando…
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway
Background: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the recurrence and resistance of OSCC after chemo/radioresistance remains a major bottleneck for its effective treatment. Molecul...
Autores principales: | Pai, Shin, Yadav, Vijesh Kumar, Kuo, Kuang-Tai, Pikatan, Narpati Wesa, Lin, Chun-Shu, Chien, Ming-Hsien, Lee, Wei-Hwa, Hsiao, Michael, Chiu, Shao-Chih, Yeh, Chi-Tai, Tsai, Jo-Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584253/ https://www.ncbi.nlm.nih.gov/pubmed/34768921 http://dx.doi.org/10.3390/ijms222111492 |
Ejemplares similares
-
BX-795 inhibits HSV-1 and HSV-2 replication by blocking the JNK/p38 pathways without interfering with PDK1 activity in host cells
por: Su, Ai-rong, et al.
Publicado: (2017) -
FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1
por: Yang, Qing, et al.
Publicado: (2022) -
MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin
por: Qian, Yan, et al.
Publicado: (2020) -
PKCθ-Mediated PDK1 Phosphorylation Enhances T Cell Activation by Increasing PDK1 Stability
por: Kang, Jung-Ah, et al.
Publicado: (2017) -
Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia
por: Peng, F, et al.
Publicado: (2018)